DUBLIN--(BUSINESS WIRE)--The "Bispecific CD3 Molecules in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.
There is a considerable and robust commercial drug pipeline of T-cell redirecting therapies by bispecific compounds that targets various tumor antigens expressed by malignant cells, and CD3 expressed by the T-cell. Upon binding to both targets, these compounds redirect T-cell cytotoxicity toward the malignant cells and effectively eradicate them.
Bispecific CD3 Molecules in Oncology: Analytical Tool is the most up to date and comprehensive commercial pipeline review and competitive assessment available on this hot and fast moving area in immune-oncology. This unique product is truly the only one of its kind and is designed to give you a competitive edge in your bispecific CD3 drug intelligence.
Your Bispecific CD3 Molecules in Oncology: Analytical Tool is based on two decades of proven methodology in serving clients with interest in:
- Target Scouting
- Early & Late Stage Pipeline Analysis
- Biomarker/Companion Diagnostic Analysis
- Deal & Alliance Analysis
- Combination Therapy Analysis
- Clinical Trial Results Analysis
- Indication Selection & Expansion Analysis
- First-in-Class Analysis
- Drug Repositioning
- Pipeline Analysis by Targeted Pathways
Your Bispecific CD3 Molecules in Oncology: Analytical Tool covers more than 45 companies plus partners who are today developing 96 bispecific CD3 drugs where of 83 are in active developmental in cancer across 39 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.
For more information about this report visit https://www.researchandmarkets.com/research/x4nc5p/bispecific_cd3?w=4
